E Fund Management Co. Ltd. Makes New $3.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• E Fund Management purchased 5,158 Regeneron shares worth approximately $3.22 million, while institutional investors collectively own 83.31% of the company.
• Regeneron reported quarterly EPS of $14.29, exceeding estimates of $10.16, while revenue rose 16.7% year over year to $4.29 billion. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $801.70.
• The FDA approved Regeneron’s Pasatru as the first treatment for the rare bone disorder FOP, strengthening its rare-disease portfolio, although securities litigation tied to the failed fianlimab-Libtayo melanoma trial remains a risk.

E Fund Management Co. Ltd. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,158 shares of the biopharmaceutical company's stock, valued at approximately $3,216,000.

Other hedge funds have also recently added to or reduced their stakes in the company. WPG Advisers LLC boosted its stake in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 25 shares during the last quarter. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $26,000. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Finally, Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 3.8%

NASDAQ:REGN opened at $840.84 on Thursday. The stock has a 50-day simple moving average of $688.35 and a 200 day simple moving average of $715.30. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $844.92. The company has a market cap of $86.57 billion, a PE ratio of 20.78, a PEG ratio of 1.38 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals's revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $12.81 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.29%.

Analyst Ratings Changes

Several research firms have recently issued reports on REGN. Cantor Fitzgerald raised their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Wells Fargo & Company upped their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Citigroup increased their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a "neutral" rating in a research note on Monday, August 3rd. Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Finally, TD Cowen boosted their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a "buy" rating in a research report on Thursday, April 23rd. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $801.70.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru as the first and only treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder involving abnormal bone formation in soft tissues. In the placebo-controlled OPTIMA trial, Pasatru reduced new heterotopic ossification lesions by at least 90% at 56 weeks and significantly reduced clinician-assessed flare-ups. The approval adds a potential commercial product and strengthens Regeneron’s rare-disease portfolio. Reuters FDA approval article
• Positive Sentiment: The Pasatru approval is supported by meaningful clinical efficacy in a condition with limited treatment options, potentially giving Regeneron pricing and market-entry advantages in a highly specialized market. The financial contribution may initially be limited by FOP’s very small patient population, but the regulatory milestone can improve long-term pipeline value. Pasatru approval announcement
• Neutral Sentiment: Regeneron announced upcoming investor conference presentations by management. The events could provide additional details on Pasatru’s launch, the broader pipeline and financial outlook, but the announcement itself does not change current earnings expectations. Regeneron investor conference announcement
• Positive Sentiment: Leerink Partners raised its price target for REGN to $824, signaling continued analyst support for the shares, although the target may not fully reflect the latest trading level. Leerink Partners price target article
• Negative Sentiment: Several law firms publicized securities class actions and a September 14, 2026 lead-plaintiff deadline concerning allegations that Regeneron misrepresented risks surrounding the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, creating litigation costs, reputational risk and uncertainty around the oncology pipeline. These notices largely repeat the same underlying allegations rather than represent new operational developments. Regeneron class action notice

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company's stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock valued at $1,090,030 over the last three months. Insiders own 6.97% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source